Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML

Curtis Lachowiez, Andy Kaempf, Carolyn Lehn, Tara Lundberg Williams, Gabriella Sheldon, Jessica Leonard, Gabrielle Meyers, Arpita Gandhi, Jennifer Saultz, Brandon Hayes-Lattin, Richard Maziarz, Rachel Cook, Ronan Swords, Gordon Mills, Theodore Braun

Blood (2025) 146 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2025-1649

Published: 2025

Journal Articles

Standard tyrosine kinase inhibitor dose versus dose de-escalation prior to treatment-free remission attempt in chronic myeloid leukemia: A single-center 25-year retrospective study

Mark Pusung, Christopher Eide, Nicola Long, Cristina Tognon, Andy Kaempf, Diana Brewer, Theodore Braun, Michael Heinrich, Brian Druker

Blood (2025) 146 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2025-2011

Published: 2025

Journal Articles

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Virginia Tan, Jean Sabile, Amrita Desai, Arpita Gandhi, Jennifer Saultz, Gabrielle Meyers, Laura Newell, Rachel Cook, Elie Traer, Curtis Lachowiez, Ronan Swords, Richard Maziarz, Theodore Braun, Brandon Hayes-Lattin, Jessica Leonard

Blood (2025) 146 (Supplement 1): 3372.

https://doi.org/10.1182/blood-2025-3372

Published: 2025

Journal Articles

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Blood (2025) 146 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2025-3354

Published: 2025

Journal Articles

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Blood (2025) 146 (Supplement 1): 1083.

https://doi.org/10.1182/blood-2025-1083

Published: 2025

Journal Articles

Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia

Sangeetha Venugopal, Neil Palmisiano, Guru Subramanian Guru Murthy, Theodore Braun, Alex Ambinder, Jonathan Feld, Sharad Khurana, Stephen Strickland, Rajneesh Nath, Konstantinos Sdrimas, Raquel Ruiz, Beatriz Bruno, Sonia Gutierrez, Douglas Faller, Ana Limon, Amir Fathi

Blood (2025) 146 (Supplement 1): 5197.

https://doi.org/10.1182/blood-2025-5197

Published: 2025

Journal Articles

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

Theodore Braun, MD PhD, Cody Coblentz, Sarah A Carratt, PhD BS, Mariam Okhovat, PhD, Amy Foley, MEng., Zachary Schonrock, BS, Kimberly Nevonen, Rhonda E. Ries, MA, Shannon K. McWeeney, PhD, Claus Nerlov, PhD, Soheil Meshinchi, MD PhD, Lucia Carbone, PhD, Brian J. Druker, Julia E. Maxson, PhD

Blood (2019) 134 (Supplement_1): 543.

https://doi.org/10.1182/blood-2019-124773

Published: 2019

Journal Articles

SETBP1 Mutations Accelerate NRAS-Mutant Leukemia

Sarah A Carratt, PhD BS, Zachary Schonrock, BS, Theodore Braun, MD PhD, Cody Coblentz, Amy Foley, MEng., Julia E. Maxson, PhD

Blood (2019) 134 (Supplement_1): 1254.

https://doi.org/10.1182/blood-2019-125125

Published: 2019

Journal Articles

Single Cell RNA Sequencing Identifies a Crucial Role for ASXL1 in Neutrophil Development

Theodore Braun, MD PhD, Theresa Lusardi, PhD, Trevor Enright, MS, Zachary Schonrock, BS, Cody Coblentz, Hisham Mohamed, PhD, Brian J. Druker, Julia E. Maxson, PhD

Blood (2019) 134 (Supplement_1): 212.

https://doi.org/10.1182/blood-2019-125022

Published: 2019

Journal Articles

Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia

Theodore Braun, MD PhD, Amy Foley, MEng., Brian J. Druker, MD, Julia E. Maxson

Blood (2018) 132 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2018-99-119213

Published: 2018

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML

Standard tyrosine kinase inhibitor dose versus dose de-escalation prior to treatment-free remission attempt in chronic myeloid leukemia: A single-center 25-year retrospective study

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

SETBP1 Mutations Accelerate NRAS-Mutant Leukemia

Single Cell RNA Sequencing Identifies a Crucial Role for ASXL1 in Neutrophil Development

Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only